Novartis AG (NVS)

76.35
0.11 0.14
NYSE : Health Care
Prev Close 76.24
Open 75.64
Day Low/High 75.62 / 76.65
52 Wk Low/High 66.93 / 83.58
Volume 1.86M
Avg Volume 2.68M
Exchange NYSE
Shares Outstanding 2.37B
Market Cap 177.13B
EPS 2.80
P/E Ratio 26.46
Div & Yield 2.72 (3.60%)

Latest News

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.

Stock Futures See More Gains on a Stream of Positive Earnings

Stock Futures See More Gains on a Stream of Positive Earnings

Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.

Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth

Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth

Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Weekly Roundup

Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.

Updates on Some Names in Our Portfolio

Taking a look at Facebook, Arconic, Magellan and others.

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps

The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.

Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait

Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait

The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite's competing 'CAR-T' KTE-C19 in the same DLBCL patients.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials

Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials

Novartis shares fell after it said a potentially key cardiovascular treatment had failed a global clinical trial, putting doubt over the group's ability to offset slowing heart disease drug sales.

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks fall for a second day on Tuesday, the first back-to-back decline since January, as a selloff in health care spoils attempts by the market to push higher.

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks slump Tuesday as a selloff in health care spoils an attempt by the market to push higher.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks are in flux on Tuesday as Donald Trump makes vague promises to lower drug prices, while Republicans unveil their bill to tackle health care reform.

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.

Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea

Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea

Novartis shares fell in Zurich Thursday after it had the sales of some of its drugs banned in South Korea following a fine from food and drug safety officials.

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's sovereign wealth fund, the world's biggest and a key investor in Apple and Alphabet, earned more than $53 billion last year as equity returns surged.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Novartis Shows the World a Take of 2 Charts

Novartis Shows the World a Take of 2 Charts

Novartis has seen some very aggressive buying the past five months -- time to join in.

Ring the Register With These Upcoming Spinoffs

Ring the Register With These Upcoming Spinoffs

Numerous studies show that corporate carve outs deliver robust returns.